Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion–Negative Early Breast Cancers Without Adjuvant Systemic Therapies Stephen K. Chia, Caroline H. Speers, Cicely J. Bryce, Malcolm M. Hayes, Ivo A. Olivotto From the Division of Medical Oncology, Breast Cancer Outcomes Unit, Division of Pathology and Division of Radiation Oncology, British Columbia Cancer Agency (BCCA), Vancouver and Victoria, Canada Address reprint requests to Stephen Chia, MD, Division of Medical Oncology, British Columbia Cancer Agency, 600 West 10th Ave, Vancouver, BC Canada, V5Z 4E6; e-mail: schia@bccancer.bc.ca PURPOSE: To discuss the absolute benefits from adjuvant systemic therapy knowledge of long-term outcomes and baseline risks of relapse and disease-specific survival are required. We assessed the 10-year outcomes in a population-based cohort of node-negative (N–) lymphovascular negative (LV–) early breast cancers diagnosed from 1989 to 1991 who did not receive adjuvant systemic therapy. METHODS: One thousand one hundred eighty-seven cases of pT1–2N0 LV– breast cancers with a median follow-up of 10.4 years were reviewed. Kaplan-Meier survival curves for relapse free survival (RFS), breast cancer–specific survival (BCSS) and overall survival (OS) were compared with log-rank tests with cohorts stratified for tumor size and grade. RESULTS: The median age of this series was 62 years. Four hundred thirty tumors were 1 cm in diameter (cohort 1), 507 were 1.1–2 cm (cohort 2), and 250 were 2.1 to 5 cm in diameter (cohort 3). The 10-year outcomes for cohorts 1, 2, and 3, respectively, were significantly different: RFS, 82%, 75%, and 66%; BCSS, 92%, 90%, and 77%; and OS, 79%, 78%, and 66%. Tumor grade significantly altered outcome within size cohorts, particularly in pT1N0 breast cancers. CONCLUSION: This study provides detailed information on the continued relapse and breast cancer death rate to 10 years of follow-up. Specifically, without adjuvant systemic therapy, patients with LV–, N – breast cancer had a 25% 10-year risk of relapse and a corresponding 10-year breast cancer death rate of 10% if they had either a grade 3 tumor 1 cm, a grade 2 to 3 tumor from 1.1 to 2 cm, or any grade tumor greater than 2 cm. Presented in part at the 39th American Society of Clinical Oncology Annual Meeting, May 18–21, 2002, Orlando, FL. Journal of Clinical Oncology, Vol 22, No 9 (May 1), 2004: pp. 1630-1637 DOI: 10.1200/JCO.2004.09.070 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.